India has granted market authorisation to QDENGA, a dengue vaccine developed by Takeda Biopharmaceuticals. The approval was issued by the Drug Controller General of India (DCGI), making it the first dengue vaccine cleared for use in the country.
Key Developments
- Authorization granted in 2026 for individuals aged 4 to 60 years.
- Vaccine schedule: two doses administered three months apart.
- Designed to protect against all four serotypes of dengue virus.
- Price for the Indian market has not yet been announced.
- India accounts for roughly one‑third of the global dengue burden.
Important Facts
According to the World Health Organization (WHO), about 100–400 million dengue infections occur worldwide each year, putting half of the global population at risk. India is one of the five nations that feature among the 30 most highly endemic countries for dengue.
Exam Relevance
Understanding the approval process of a new vaccine touches upon several UPSC topics: the role of the DCGI in health governance, the public‑health challenge posed by dengue, and the economic implications of introducing a costly immunisation programme. Aspirants should link this development to broader themes such as disease surveillance, health infrastructure, and the impact of pharmaceutical innovation on national health security.
Way Forward
Policy makers need to address three immediate priorities: (1) finalise a pricing strategy that ensures affordability while sustaining supply; (2) integrate the vaccine into existing immunisation schedules, especially in high‑risk states; and (3) strengthen vector‑control measures to complement vaccination. Continuous monitoring of vaccine efficacy and safety will be essential for scaling up the programme and achieving long‑term reduction in dengue morbidity and mortality.